HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Expands Infant Formula Safety, Supply Workload For FDA, Industry In User Fees Bill

Executive Summary

HELP Committee passes five-year reauthorization of FDA drug, medical device and biosimilar user fees with separate provisions expanding agency’s authority to regulate infant formula manufacturing and marketing and establishing Office of Critical Foods in CFSAN.

You may also be interested in...



House Appropriators Reject Docking FDA FY2023 Budget Until Formula Crisis Report Provided

First-term Iowa Republican Hinson had support from Democrat as well as other GOP members for withholding part of commissioner office’s FY2023 budget. Opposition from a self-acknowledged unlikely source, committee chair DeLauro, steered votes toward rejecting the proposal.

US Bill To Radically Overhaul Cosmetics Regulations Passes Senate HELP Committee

One voice emerged from the committee markup session as a potential cosmetics industry ally. In his opening remarks, ranking member Richard Burr, R-NC, said, “I worry that we’re rewarding bad behavior. Is this the time to expand FDA authority in any space, including diagnostic tests, cosmetics, and dietary supplements?”

Abbott US Nutrition Chief Testifies ‘Safety First’ During House Hearing On Formula Shortage

Abbott's s Christopher Calamari, Gerber's Scott Fitz and Reckitt Robert Cleveland didn't have ng answers about immediately solving supply shortage or about preventing another one when they testified before Oversight and Investigation Subcommittee.

Latest News
UsernamePublicRestriction

Register

RS152646

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel